New Alzheimer's drugs from Ei­sai and Lil­ly: Ex­pec­ta­tions set at $10B+ in com­bined sales by 2030

An FDA ap­proval for Eli Lil­ly’s amy­loid-tar­get­ed Alzheimer’s drug do­nanemab seems all but cer­tain, and it’s now pre­dict­ed that do­nanemab and Leqem­bi, the Alzheimer’s treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.